Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.
Launched by UNIVERSITY HOSPITAL MUENSTER · Sep 2, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option for patients with problems in the aortic arch, which is the curved part of the main artery in the body. The treatment involves using a special device called a triple inner branched aortic arch stentgraft, designed to help manage conditions like aneurysms (bulges in the artery) or dissections (tears in the artery). The trial is being conducted across multiple medical centers and is currently recruiting participants.
To be eligible for this study, participants must be at least 18 years old and have a specific issue related to the aortic arch that can be treated with the stentgraft. They will need to be available for follow-up appointments and provide written consent to participate. Unfortunately, women who could potentially become pregnant and anyone under 18 cannot join the study. Participants can expect to receive the new treatment and will be monitored closely to see how well it works and to ensure their safety throughout the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • Presence of Aortic arch pathology
- • Treatment planned with triple inner branch from Terumo Aortic
- • Availability of the patients during the follow up period
- • Informing patients about the study and providing written informed consent
- Exclusion Criteria:
- • Women of childbearing age
- • Patients under 18 years
About University Hospital Muenster
University Hospital Münster is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and developing new therapeutic strategies. With a strong focus on collaboration and ethical research practices, University Hospital Münster plays a pivotal role in translating scientific discoveries into practical applications, fostering a culture of inquiry that benefits both the medical community and the patients it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Münster, , Germany
Patients applied
Trial Officials
Alexander Oberhuber, MD, PhD
Study Chair
Department of Vascular and Endovascular Surgery University Hospital Münster
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials